Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous, and haemodialysis use. It prevents and treats blood clots in patients at risk of deep vein thrombosis, pulmonary embolism, or requiring anticoagulation during dialysis.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Enoxaparin sodium is a low molecular weight heparin used to prevent and treat thromboembolic disorders.

- Prevention of deep vein thrombosis: reduces the incidence of DVT in surgical or immobilised patients. - Treatment of pulmonary embolism: facilitates clot resolution and prevents recurrence of emboli. - Anticoagulation during hemodialysis: maintains circuit patency and reduces clot formation during dialysis sessions.

Enoxaparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site bruising or pain - Minor bleeding (e.g., gum, nosebleeds) - Nausea or vomiting - Headache - Elevated liver enzymes - Mild anemia

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Allergic reactions (rash, urticaria, anaphylaxis) - Skin necrosis at injection sites - Spinal or epidural hematoma - Acute adrenal hemorrhage

Before using Ledraxen, consider the following safety measures.

- Assess bleeding risk: evaluate patient history for recent surgery or bleeding disorders. - Monitor platelet count: check regularly for signs of heparin‑induced thrombocytopenia. - Adjust dose in renal impairment: reduce dosage in patients with decreased kidney function. - Avoid concomitant anticoagulants: do not combine with other blood thinners unless clinically indicated. - Use caution in pregnancy: only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin sodium can interact with several medications that affect haemostasis.

Major Interactions (Avoid): - Other anticoagulants (warfarin, direct thrombin inhibitors) - Antiplatelet agents (aspirin, clopidogrel) - Fibrinolytic therapy (tPA, streptokinase) - Non‑steroidal anti‑inflammatory drugs (NSAIDs) - Spinal or epidural anesthesia (risk of hematoma)

Moderate Interactions (Monitor Closely): - Factor Xa inhibitors (rivaroxaban, apixaban) – increased bleeding risk. - Certain antibiotics (e.g., vancomycin) – may potentiate anticoagulant effect. - Renal‑clearing drugs – monitor renal function and adjust dose as needed.